Vijaya Diagnostic Centre Ltd
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.[1]
- Market Cap ₹ 9,740 Cr.
- Current Price ₹ 949
- High / Low ₹ 1,277 / 725
- Stock P/E 67.7
- Book Value ₹ 77.5
- Dividend Yield 0.10 %
- ROCE 21.7 %
- ROE 19.8 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 12.4 times its book value
- Working capital days have increased from 7.66 days to 63.7 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
251 | 293 | 339 | 377 | 462 | 459 | 548 | 681 | |
171 | 184 | 206 | 211 | 259 | 277 | 327 | 408 | |
Operating Profit | 80 | 108 | 133 | 166 | 204 | 182 | 221 | 273 |
OPM % | 32% | 37% | 39% | 44% | 44% | 40% | 40% | 40% |
7 | 10 | 15 | 12 | 13 | 14 | 19 | 17 | |
Interest | 5 | 14 | 15 | 15 | 16 | 21 | 24 | 27 |
Depreciation | 26 | 40 | 49 | 50 | 53 | 62 | 57 | 71 |
Profit before tax | 55 | 65 | 83 | 112 | 147 | 114 | 159 | 193 |
Tax % | 37% | 29% | 25% | 24% | 25% | 25% | 25% | 26% |
35 | 46 | 63 | 85 | 111 | 85 | 120 | 144 | |
EPS in Rs | 77.44 | 101.29 | 138.00 | 18.64 | 10.76 | 8.29 | 11.61 | 13.94 |
Dividend Payout % | -0% | -0% | -0% | -0% | 9% | 12% | 9% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 14% |
TTM: | 24% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 10% |
TTM: | 34% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 43% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 18% |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 |
Reserves | 157 | 203 | 270 | 354 | 458 | 535 | 647 | 785 |
33 | 146 | 161 | 141 | 183 | 248 | 259 | 320 | |
39 | 53 | 46 | 41 | 62 | 61 | 66 | 158 | |
Total Liabilities | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 |
119 | 259 | 272 | 268 | 370 | 524 | 742 | 865 | |
CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 70 |
Investments | 73 | 69 | 55 | 28 | 54 | 139 | 109 | 185 |
39 | 76 | 146 | 236 | 255 | 163 | 123 | 154 | |
Total Assets | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
62 | 91 | 106 | 130 | 158 | 165 | 183 | 224 | |
-98 | -90 | -31 | -130 | -123 | -110 | -141 | -182 | |
-8 | -7 | -30 | -49 | -31 | -42 | -45 | -52 | |
Net Cash Flow | -44 | -6 | 46 | -49 | 4 | 13 | -2 | -9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 12 | 11 | 9 | 6 | 8 | 8 | 11 | 8 |
Inventory Days | 24 | 20 | 23 | 17 | 22 | 13 | 29 | 21 |
Days Payable | 176 | 196 | 180 | 142 | 110 | 172 | 184 | 143 |
Cash Conversion Cycle | -140 | -165 | -149 | -118 | -81 | -152 | -144 | -114 |
Working Capital Days | -41 | -40 | -38 | -15 | -23 | -25 | -16 | 64 |
ROCE % | 28% | 23% | 27% | 28% | 18% | 20% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - Allotment of 50,833 Equity Shares of Face Value of Rs. 1/- each pursuant to exercise options under ESOP Plan.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report confirms full regulatory compliance for FY ended March 31, 2025.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 20 May
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
15 May - Q4 FY25 earnings: 24% revenue growth, 6 new hubs launched, FY26 capex ~INR150 Cr, margin dip expected due to expansion.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 May
Annual reports
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024TranscriptNotesPPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Dec 2023TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
Market Leadership
The company is the largest integrated diagnostic chain in South India. [1] It was among the first in South India to offer PET-CT scans. [2]